183 related articles for article (PubMed ID: 20522552)
1. GRIM-19 and p16(INK4a) synergistically regulate cell cycle progression and E2F1-responsive gene expression.
Sun P; Nallar SC; Raha A; Kalakonda S; Velalar CN; Reddy SP; Kalvakolanu DV
J Biol Chem; 2010 Sep; 285(36):27545-52. PubMed ID: 20522552
[TBL] [Abstract][Full Text] [Related]
2. p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1.
Al-Khalaf HH; Colak D; Al-Saif M; Al-Bakheet A; Hendrayani SF; Al-Yousef N; Kaya N; Khabar KS; Aboussekhra A
PLoS One; 2011; 6(7):e21111. PubMed ID: 21799732
[TBL] [Abstract][Full Text] [Related]
3. Identification of a structural motif in the tumor-suppressive protein GRIM-19 required for its antitumor activity.
Nallar SC; Kalakonda S; Sun P; Ohmori Y; Hiroi M; Mori K; Lindner DJ; Kalvakolanu DV
Am J Pathol; 2010 Aug; 177(2):896-907. PubMed ID: 20595633
[TBL] [Abstract][Full Text] [Related]
4. GRIM-19 function in cancer development.
Moreira S; Correia M; Soares P; Máximo V
Mitochondrion; 2011 Sep; 11(5):693-9. PubMed ID: 21664299
[TBL] [Abstract][Full Text] [Related]
5. GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism.
Nallar SC; Kalvakolanu DV
Cytokine Growth Factor Rev; 2017 Feb; 33():1-18. PubMed ID: 27659873
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels.
Kalakonda S; Nallar SC; Gong P; Lindner DJ; Goldblum SE; Reddy SP; Kalvakolanu DV
Am J Pathol; 2007 Oct; 171(4):1352-68. PubMed ID: 17823279
[TBL] [Abstract][Full Text] [Related]
7. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis.
Nallar SC; Kalakonda S; Lindner DJ; Lorenz RR; Lamarre E; Weihua X; Kalvakolanu DV
J Biol Chem; 2013 Mar; 288(11):7930-7941. PubMed ID: 23386605
[TBL] [Abstract][Full Text] [Related]
9. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo.
Wang GM; Ren ZX; Wang PS; Su C; Zhang WX; Liu ZG; Zhang L; Zhao XJ; Chen G
Oncol Rep; 2014 Aug; 32(2):573-80. PubMed ID: 24899100
[TBL] [Abstract][Full Text] [Related]
10. Vitamin C inhibits benzo[a]pyrene-induced cell cycle changes partly via cyclin D1/E2F pathway in human embryo lung fibroblasts.
Gao A; Liu BC; Shit XL; Huang CS; Jia XW; You BR; Ye M; Shen FH; Du HJ
Biomed Environ Sci; 2006 Jun; 19(3):239-44. PubMed ID: 16944783
[TBL] [Abstract][Full Text] [Related]
11. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
13. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
14. GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis.
Kalakonda S; Nallar SC; Lindner DJ; Sun P; Lorenz RR; Lamarre E; Reddy SP; Kalvakolanu DV
Oncogene; 2014 Jun; 33(24):3195-204. PubMed ID: 23851499
[TBL] [Abstract][Full Text] [Related]
15. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway.
Jung JK; Arora P; Pagano JS; Jang KL
Cancer Res; 2007 Jun; 67(12):5771-8. PubMed ID: 17575144
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-induced tumor suppressors: a GRIM story.
Kalvakolanu DV; Nallar SC; Kalakonda S
Cytokine; 2010; 52(1-2):128-42. PubMed ID: 20382543
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.
Tin AS; Sundar SN; Tran KQ; Park AH; Poindexter KM; Firestone GL
Anticancer Drugs; 2012 Apr; 23(4):370-9. PubMed ID: 22185819
[TBL] [Abstract][Full Text] [Related]
18. Retinoblastoma (Rb) tumor-suppressor pathway alterations in meningeal hemangiopericytomas: High E2F transcription factor 1 expression and loss of Rb expression: study by double immunofluorescence staining and laser-scanning confocal microscopy.
Martinez JC; Palomino JC; Samaniego R; Sepulveda JM; Cabello A; Ricoy JR
Cancer; 2008 Jul; 113(1):166-74. PubMed ID: 18459177
[TBL] [Abstract][Full Text] [Related]
19. GRIM-19 represses the proliferation and invasion of cutaneous squamous cell carcinoma cells associated with downregulation of STAT3 signaling.
Wu N; Hui H; Cui L; Yang F
Biomed Pharmacother; 2017 Nov; 95():1169-1176. PubMed ID: 28926927
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage.
Al-Khalaf HH; Mohideen P; Nallar SC; Kalvakolanu DV; Aboussekhra A
J Biol Chem; 2013 Dec; 288(49):35511-25. PubMed ID: 24163379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
